Abstract
Since its regulatory approval over a half-century ago, botulinum toxin has evolved from one of the most potent neurotoxins known to becoming routinely adopted in clinical practice. Botulinum toxin, a highly potent neurotoxin produced by Clostridium botulinum, can cause botulism illness, characterized by widespread muscle weakness due to inhibition of acetylcholine transmission at neuromuscular junctions. The observation of botulinum toxin’s anticholinergic properties led to the investigation of its potential benefits for conditions with an underlying etiology of cholinergic transmission, including autonomic nervous system dysfunction. These conditions range from disorders of the integument to gastrointestinal and urinary systems. Several formulations of botulinum toxin have been developed and tested over time, significantly increasing the availability of this treatment for appropriate clinical use. Despite the accelerated and expanded use of botulinum toxin, there lacks an updated comprehensive review on its therapeutic use, particularly to treat autonomic dysfunction. This narrative review provides an overview of the effect of botulinum toxin in the treatment of autonomic dysfunction and summarizes the different formulations and dosages most widely studied, while highlighting reported outcomes and the occurrence of any adverse events.
| Original language | English |
|---|---|
| Article number | 96 |
| Journal | Toxins |
| Volume | 16 |
| Issue number | 2 |
| DOIs | |
| State | Published - Feb 2024 |
Bibliographical note
Publisher Copyright:© 2024 by the authors.
Funding
We acknowledge the support of funding agencies for the work of our authors. L.R. is supported by the University of British Columbia Faculty of Medicine Summer Student Ship Research Program Award. A.V.K. holds an Endowed in rehabilitation medicine at the University of British Columbia, and his laboratory is supported by funds from the Canadian Institute for Health Research, Rick Hansen Foundation, Praxis Spinal Cord Institute, US Department of Defense, International Spinal Research Trust, and the Wings for Life Spinal Cord Research Foundation. R.N.M. is supported by the Paralyzed Veterans of America Fellowship (#3196). R.S. is supported by the Wings for Life Spinal Cord Research Foundation (Proj 260) and the US Department of Defense (SC21007). C.S. is supported by Paralyzed Veterans of America (#3189), Rick Hansen Foundation (#2007-21), and the Canadian Institute for Health Research (#489969).
| Funders | Funder number |
|---|---|
| U.S. Department of Defense | |
| Paralyzed Veterans of America | 3189, 2007-21, 489969 |
| Wings for Life Spinal Cord Research Foundation | SC21007, Proj 260, 3196 |
| Praxis Spinal Cord Institute | |
| Faculty of Medicine, University of British Columbia | |
| Rick Hansen Foundation | |
| Canadian Institutes of Health Research | |
| International Spinal Research Trust | |
| Univ. of Northern British Columbia |
Keywords
- autonomic dysfunction
- bacterial toxin
- botulinum toxin
ASJC Scopus subject areas
- Toxicology
- Health, Toxicology and Mutagenesis